Gonzalo Rodriguez-Berriguete
BSc Biol, PhD
Senior Researcher
- Senior Researcher
- MSc in Radiobiology, Course Co-Director
Tumour Radiosensivity
I am a Senior Postdoctoral Researcher in the Tumour Radiosensitivity Group at the University of Oxford’s Department of Oncology. My research focuses on understanding the molecular mechanisms that determine sensitivity to ionising radiation and on identifying and developing new therapeutic strategies to improve radiotherapy response.
In my research, I employ functional screening methods and a broad range of in vitro and in vivo techniques, as well as the analysis of patient samples and data. In particular, I have focused on targeting DNA repair pathways like Polθ-mediated repair, overcoming tumour hypoxia through mitochondrial inhibition, developing functional screening approaches to discover new therapeutic targets and biomarkers, and developing new drugs for combination with radiotherapy.
Recent publications
Structure-guided optimisation of fenofibrate-derived oxidative phosphorylation inhibitors to modify tumour hypoxia.
Journal article
Holt-Martyn JP. et al, (2026), RSC Med Chem, 17, 2925 - 2935
SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy.
Journal article
Rodriguez-Berriguete G. et al, (2026), Sci Adv, 12
UPR-induced intracellular C5aR1 promotes adaptation to the hypoxic tumour microenvironment.
Journal article
Suwa T. et al, (2025), Cell Death Dis, 16
UPR-induced intracellular C5aR1 promotes adaptation to the hypoxic tumour microenvironment by regulating tumour cell fate
Preprint
Suwa T. et al, (2024)
Antitumour effect of the mitochondrial complex III inhibitor Atovaquone in combination with anti-PD-L1 therapy in mouse cancer models.
Journal article
Rodriguez-Berriguete G. et al, (2024), Cell Death Dis, 15